Bone Biologics Seeks Approval for Reverse Split and Warrant Issuance to Maintain Nasdaq Listing

summarizeSummary

Bone Biologics filed a preliminary proxy seeking shareholder approval for a reverse stock split and the issuance of over 4.3 million warrant shares to maintain Nasdaq listing and raise up to $6 million.

check_boxKey Events · Corporate Governance and Compliance · BBLG

• Reverse Stock Split Proposed

  Board seeks approval for a reverse split between 1-for-2 and 1-for-10 to raise the stock price above Nasdaq's $1.00 minimum bid requirement. Current price is $0.6251.

• Warrant Issuance Approval Sought

  Proposal Four asks shareholders to approve issuance of 4,352,115 shares underlying warrants (Series F, Series G, and placement agent warrants) at exercise prices of $1.42 and $1.775, potentially raising $6 million.

• Nasdaq Listing at Risk

  Company states failure to approve the reverse split could lead to delisting from Nasdaq, which would limit access to capital markets and reduce liquidity.

• Dilution Impact

  If all warrants are exercised, outstanding shares would increase from 2,011,057 to over 6.3 million, diluting existing shareholders by more than 200%.

auto_awesomeAnalysis · BBLG · Industrial Applications And Services

Bone Biologics is asking shareholders to approve a reverse stock split (1-for-2 to 1-for-10) and the potential issuance of over 4.3 million warrant shares to comply with Nasdaq listing rules. The company's stock trades near its 52-week low at $0.6251, below the $1.00 minimum bid requirement, and the reverse split is designed to boost the share price to avoid delisting. The warrant issuance, if approved, could raise up to $6 million in additional capital but would significantly dilute existing shareholders. Failure to approve these proposals could jeopardize the company's Nasdaq listing and its ability to fund operations.